Skip to Main Content

After years of anticipation, the US Food and Drug Administration released a final guideline for naming both pricey biologic medicines and identical, but lower-cost versions that are known as biosimilars. However, the agency appears to have adopted a position that may give an edge to brand-name drug makers, a significant move given the huge sales that are at stake.

The guideline is somewhat cumbersome but, essentially, requires companies to add four-letter suffixes to the drug names that would allow physicians to distinguish between the original biologic and the new biosimilar. (A biosimilar, you may recall, is a distinct regulatory description for a medicine that is supposed to produce the same clinical result as a brand-name biologic.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!